Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab probably leads to lower infection with SARS‐CoV‐2 by day 30 compared with placebo (moderate certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed SARS‐CoV‐2 infection · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab leads to lower infection with SARS‐CoV‐2 by day 30 compared with placebo (high certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab leads to lower development of clinical COVID‐19 symptoms within 30 days compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in admission to hospital by day 30 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review